AbCellera Biologics (ABCL) Leases (2021 - 2025)
Historic Leases for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2025 value amounting to $137.9 million.
- AbCellera Biologics' Leases rose 10186.77% to $137.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.9 million, marking a year-over-year increase of 10186.77%. This contributed to the annual value of $66.6 million for FY2024, which is 887.6% down from last year.
- According to the latest figures from Q3 2025, AbCellera Biologics' Leases is $137.9 million, which was up 10186.77% from $136.9 million recorded in Q2 2025.
- Over the past 5 years, AbCellera Biologics' Leases peaked at $137.9 million during Q3 2025, and registered a low of $6.6 million during Q1 2022.
- Its 5-year average for Leases is $65.6 million, with a median of $68.5 million in 2024.
- Its Leases has fluctuated over the past 5 years, first surged by 63246.75% in 2023, then plummeted by 2616.97% in 2025.
- Over the past 5 years, AbCellera Biologics' Leases (Quarter) stood at $19.8 million in 2021, then skyrocketed by 308.27% to $80.8 million in 2022, then dropped by 9.52% to $73.1 million in 2023, then dropped by 8.88% to $66.6 million in 2024, then soared by 106.93% to $137.9 million in 2025.
- Its Leases stands at $137.9 million for Q3 2025, versus $136.9 million for Q2 2025 and $68.7 million for Q1 2025.